NovoCure (NVCR) Accounts Payables (2014 - 2026)

NovoCure's Accounts Payables history runs 13 years deep, the most recent figure standing at $127.2 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 33.81% year-over-year to $127.2 million; the TTM figure through Mar 2026 stood at $127.2 million (up 33.81% YoY), while the FY2025 annual figure was $122.2 million, up 16.32% from the prior year.
• Accounts Payables came in at $127.2 million for Q1 2026 at NovoCure, up from $122.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $127.2 million in Q1 2026 to a low of $69.2 million in Q1 2022.
• A 5-year average of $93.4 million and a median of $90.2 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 40.72% in 2022 and increased 3.29% in 2023, its largest moves.
• NovoCure's Accounts Payables stood at $85.2 million in 2022, then grew by 10.79% to $94.4 million in 2023, then climbed by 11.33% to $105.1 million in 2024, then rose by 16.32% to $122.2 million in 2025, then advanced by 4.1% to $127.2 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $127.2 million, $122.2 million, and $118.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison